A post-treatment analysis from 2024 found that keeping up with exercise after stopping GLP-1 receptor agonists was associated with less weight regain
Randomized controlled trials are needed to see if these medications are directly impacting mood or are mainly having an impact on mood through weight loss, said Creel
Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jdar E, Mehta R, Woo V, Lingvay I
Filed Under: Metabolic disease/endicrinology Tagged With: FDA enforcement grace period, GLP-1 drug shortages, Mounjaro supply chain, pharmaceutical compounding regulations, tirzepatide compounding Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
Endocrinology in the time of covid-19: remodelling diabetes services and emerging innovation
OZEMPIC also reduced the annual rate of change in eGFR (Figure 9), the incidence of a composite cardiovascular endpoint, consisting of non-fatal myocardial infarction (MI), non-fatal stroke, and cardiovascular death, and the incidence of all-cause death (Table 10 and Figure 8)
